Breaking News

0 321
Abeona Therapeutics ABEO Stock News

Abeona Therapeutics Inc (NASDAQ: ABEO)

Still under the radar, ABEO appears to have put the pieces in place to ramp up its presence in 2017. Regardless of the recent misinformation that has plagued the market and confused investors, there is one thing that investors can rely on 100% of the time….the fact that the FDA has been presented accurate and timely data and that oversight in trial design and implementation is intense. Importantly, and to this point, investors need to rely on company sponsored data, instead of the misplaced and intentionally misleading rhetoric being published through editorial websites.





ABEO- An Early Start In 2017

Abeona has already been active in 2017, presenting at the JP Morgan investor conference during the early part of January. Management is clearly setting the stage for potential milestones to be delivered as early as the end of February 2017, when the company is planning to release additional data from its ABO-102 phase I/II study.

ABEO investors should pay attention to the scheduled February 16th WORLDSymposium conference, where management is planning to release data on two of three patients currently enrolled in the low dose cohort of the ABO-102 trial. The company is expected to release neurocognitive data from each patient, which if positive, may lead ABEO to initiate discussions with the FDA to designate breakthrough designation for the therapy. Additionally, ABEO may be in a position to further ask the FDA to grant a registration trial and begin the process of designing a mutually agreeable trial design.

ABEO is planning to discuss both options prior to the end of February 2017, perhaps an early indication of company confidence.


WORLDSymposium Expectations

Investors can expect some material updates at the February 16th WORLDSymposium conference. ABEO is expected to release important data related to the ABO-102 trial, specifically, 90-day and six month data from patients treated in the low dose cohort of the MPS IIIA trial. Updates on the neurological data from all three patients are expected, with a focus on at least one of the patients being treated in the high dose cohort.

Consistent with past discussions, management continues to remain confident that neurological improvement may potentially be observed in the six month follow-up, and equally as important, expects to show additional improvement in urinary GAG reductions.

The expected data release may serve as milestone moments for ABEO, and investors would be wise to pay close attention to both the conference and the data.

Bring On The Facts

Paying close attention to the near term events, with material releases expected expected within the next 30-days, ABEO may be on the verge of delivering data that can be a transformative step forward for the company. Already demonstrating unparallelled results in Sanfilippo patients, ABEO can take the next step to quiet the critics of this potentially breakthrough therapy and seize an extremely lucrative Sanfilippo market. Although the market in terms of addressable patients is small, the financial benefit from a viable therapy is not, with expectations that an approved treatment will bring an enterprise value well in excess of a billion dollars.

With over $70MM in cash and virtually no debt, ABEO is extremely well fortified financially, as the company expects to burn less than $3MM dollars per quarter.

Gene therapy is grabbing the attention of investors, and ABEO has more than its fair share of well established institutional investors believing in their science, some holding in excess of 5% of the company stock. With promising data expected, investors may be wise to pay attention to actual company data, paying less focus toward disclosed short sellers that have an agenda to spew confusing and intentionally misleading information about the company.

Analyst price targets average in the range of $12.00 per share, and if ABEO can deliver some meaningful and durable results in the middle of February, these targets may be quickly met and revised higher. Without a doubt, the next 30-days for ABEO investors may prove to be a nail biter, however, with the company already focusing upon potential dialogue with the FDA regarding BT designation, reading between the lines might not be a bad way to gauge the likelihood of positive trial results.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikipedia]

J C Penny JCP Stock News

J C Penny Company Inc (NYSE: JCP)

J C Penny is having what’s starting out as an incredible day in the market today. When the opening bell rang, the stock started on a spike toward the top. Since then, we’ve seen a bit of a correction before yet another spike, bringing the stock further and further upward. Below, we’ll talk about what we’re seeing from JCP, why, and what we’ll be watching for ahead.





What We’re Seeing From JCP

As mentioned above, J C Penny is off to what seems to be an incredibly strong day in the market today. When the opening bell rang, the stock was trading close to the flat line. However, it immediately shot upward before correcting slightly. Nonetheless, minutes ago, the spike started yet again. Currently (10:07), the stock is trading at $7.00 per share after a gain of $0.24 per share or 3.55% thus far today.

Why The Stock Is Headed Upward

Our partners at Tradespoon were the first to inform us of the spike on JCP. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to uncover the story. It seems as though the stock is gaining as the result of a key announcement that was made early this morning.


The announcement was that J C Penny is in the process of teaming up with Nike (NKE) In fact, the announcement was that Nike brand shops will soon be added in more than 600 stores. Of course, JCP has been having a rough time as of late. However, investors expect that in teaming up with NKE, the company is on its way to a strong recovery.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on JCP. In particular, we’re interested in learning how putting Nike brand shops in their stores equates to larger sales volumes. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 413
Alcobra Ltd ADHD Stock News

Alcobra Ltd (NASDAQ: ADHD)

Alcobra is having an incredibly rough day in the market today. When the opening bell rang, the stock was already well in the red. From there, we’ve seen a continuation of declines throughout the first 20 minutes or so. Unfortunately, things just aren’t looking good. Below, we’ll talk about what we’re seeing, why, and what we’ll be watching for with regard to ADHD ahead.





What We’re Seeing From ADHD

As mentioned above, Alcobra isn’t having the best of days in the market today. Unfortunately, when the market opened, the stock was already trading sell into the red. Since the opening bell, we’ve seen a continuation of the declines, bringing the stock further and further into the abyss. At the moment (9:51), ADHD is trading at $0.96 per share after a loss of $0.94 per share or 49.47% thus far today.

Why The Stock Is Falling

As is usually the case, our partners at Trade Ideas were the first to let us know that ADHD was making a run for the bottom. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long to dig up the story. Unfortunately, the declines are being caused by bad news that was released by the company early this morning.


For some time now, Alcobra has been working on an ADHD drug, which until today’s announcement was in late-stage trials. Unfortunately, it was announced today that the trials have proven to be a failure. Of course, this is overwhelmingly upsetting to investors, sending the stock downward.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ADHD. In particular, we’re interested in learning more about the company’s next steps following the failed late-stage trial. Nonetheless, we’ll keep a close eye on the news and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 816
The Rubicon Project RUBI Stock News

The Rubicon Project Inc (NYSE: RUBI)

The Rubicon Project is having an overwhelmingly strong day in the market today. When the trading session started, the stock was already trading slightly in the green. From there, the stock has been running upward all day. However, the impressive gains grew more impressive over the past few minutes as the stock spiked upward. Below, we’ll talk about what we’re seeing in the market, why, and what we’ll be watching for with regard to RUBI ahead.





What We’re Seeing From RUBI

As mentioned above, The Rubicon Project was off to a relatively strong day in the market to start. At the opening bell, the stock was already trading slightly in the green. From there, we saw a continuation of gains, bringing the stock higher minute by minute throughout the day. However, minutes ago, the stock started spiking in a big way. Currently (11:45), RUBI is trading at $8.60 per share after a gain of $0.96 per share or 12.57% thus far today. At this point, the stock has halted

Why The Stock Spiked

As is increasingly the case, our partners at Tradespoon were the first to inform us of the gains on RUBI. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to dig up the dirt. At the moment, a rumor is surfacing surrounding the company that seems to have some validity to it.


At the moment, all over social media, we’re seeing chatter surrounding The Rubicon Project. The chatter suggests that the company has hired banks to help explore strategic alternatives. Of course, when we hear things like this, the first thing we think is acquisition.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be watching RUBI incredibly closely. In particular, we’re interested in seeing if there is any validity to the rumors. If so, this could prove to be a big positive for shareholders. Nonetheless, we’ll keep close tabs on the news and bring it to you as it breaks!

Update: RUBI reopens slightly lower.

Update: Rumor confirmed. The Rubicon Project has indeed hired banks to explore strategic alternatives!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Wikimedia]

0 925
Maxim Integrated Products Inc. MXIM Stock News

Maxim Integrated Products Inc. (NASDAQ: MXIM)

Maxim Integrated Products was off to what seemed like a relatively normal day. When the market opened, the stock was trading slightly in the green. From there, we saw a continuation of slow, yet steady movement upward. However, minutes ago, that slow movement turned into a spike upward. Below, we’ll talk about what we’re seeing from MXIM, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From MXIM

As mentioned above, Maxim Integrated Products was off to a relatively strong day in the market early on. When the trading session opened, the stock was already trading in the green. From there, the stock worked its way further upward at a relatively slow pace. Nonetheless, minutes ago, that all changed minutes ago when the stock started screaming upward. Currently (10:22), MXIM is trading at $41.26 per share after a gain of $0.79 per share or 1.95% thus far today.

Why The Stock Is Spiking Upward

As soon as the spike started, we got the alert from Tradespoon that it was time to look at MXIM. When we did, the CNA Finance team started digging to see exactly what was causing the movement. In this particular case, it didn’t take long to dig up the story. While we were unable to find fundamental news that would lead to such gains, we were able to find an interesting rumor in the social space.


When you look into your favorite social network and search for Maxim Integrated Products, chances are that you will find the rumor too. The rumor is that the company is going to be taken over soon. However, it’s very vague. There is no suggestion with regard to who the buyer might be or what the price might be. Nonetheless, the rumor is definitely leading to excitement in the market.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MXIM. In particular, we’re interested in learning more about whether or not there is any validity to these rumors. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pexels]

0 1217
Twitter Inc TWTR Stock News

Twitter Inc (NYSE: TWTR)

Twitter was off to a normal day in the market. When the opening bell rang, the stock was slightly in the red. From there, it pushed slightly to the green before falling back into the red. However, minutes ago, the stock started spiking in a big way. Below, we’ll talk about what we’re seeing from TWTR, why, and what we’ll be watching for ahead.





What We’re Seeing From TWTR

As mentioned above, Twitter looked like it was off to a relatively normal day in the market today. At the open of the trading session, the stock was trading in the red. However, it didn’t take long to get to the green. From there, the stock teetered on the break-even point. That is, until minutes ago when the stock started to spike. At the moment (10:07), TWTR is trading at $17.60 per share after a gain of $0.23 per share or 1.29% thus far today.

Why The Stock Is Climbing

In this case, our partners at Tradespoon were the first to inform us of the spike on TWTR. As soon as they did, the CNA Finance team started to dig to see what was causing the movement. In this particular case, it didn’t take long to uncover the story. It seems as though the gains on the stock are being caused by yet another social network rumor.


At the moment, regardless of which social network is your favorite, if you search for Twitter, you’re likely to see the rumor. The rumor is yet another acquisition rumor, suggesting that Softbank will be taking the company over. This rumor has popped up few times since the failed auction on the company. So, we’re not expecting for it to come to fruition.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TWTR. In particular, we’re interested in learning more about this rumor. While we believe it’s not going to happen, if there is any validity here, it could be great for investors. Nonetheless, we’ll be watching the news closely and bringing it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

Groupon GRPN Stock News

Groupon Inc Common Stock (NASDAQ: GRPN)

Groupon was having what seemed to be a rough day in the market today. When the trading session opened, the stock was trading slightly in the red. From there, we saw steady declines on the stock, bringing it further and further into the abyss. However, minutes ago, things changed as the stock started to spike upward. Below, we’ll talk about what we’re seeing from GRPN, why, and what we’ll be watching for ahead.





What We’re Seeing From GRPN

As mentioned above Groupon was off to what seemed to be a rough day in the market today. At the opening of the trading session, the stock was trading slightly in the red. However, things got worse as the morning progressed. It seemed as though the only direction the stock knew was down! Nonetheless, minutes ago, that all changed as the stock started spiking upward in a big way. Currently (11:33), GRPN is trading at $3.61 per share after a gain of $0.11 per share (3.14%) thus far today.

Why The Stock Is Spiking Upward

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on GRPN. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. In this case, it didn’t take long. While we didn’t find any fundamental news released by the company that would lead to such gains, we did find something interesting in the social space.


At the moment, there’s a big rumor circling Groupon in the world of social media. That rumor is that Alibaba is going to make a bid to take the company over. This is a long awaited move, and it makes a whole lot of sense. However, it’s important to keep in mind that, at the moment, this is nothing more than a rumor. Nonetheless, it sure is getting investors excited.

What We’ll Be Watching Ahead

Moving forward, the CNA Finance team will be watching GRPN incredibly closely. In particular, we’re watching to see if there is any validity to the rumor. Of course, if Alibaba does indeed buy GRPN, it would be a great thing for investors. We’ll keep a close eye on the story and bring the news to you as it breaks!

Update: Alibaba announced it has no plans of acquiring GRPN.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

0 733
ClubCorp Holdings Inc MYCC Stock News

ClubCorp Holdings Inc (NYSE: MYCC)

ClubCorp Holdings looked like it was off to a rough day in the market today. When the opening bell rang, the stock was slightly in the red. From there, we saw slow and steady declines, bringing the stock further and further downward. However, that all changed minutes ago when the stock started to spike upward before being halted. Below, we’ll talk about what we’re seeing form MYCC, why, and what we’ll be watching for ahead.





What We’re Seeing From MYCC

As mentioned above, ClubCorp Holdings didn’t look like it was going to have a great day in the market today. In fact, at the open of the trading session, the stock was already in the red. From there, throughout most of the morning, we saw a continuation of the declines. Nonetheless, minutes ago, the direction changed in a big way as the stock spiked well into the green. Currently (11:18), MYCC is trading at $16.25 per share after a gain of $1.25 per share (8.33%) thus far today. The stock is currently halted.

Why The Stock Is Spiking

As is normally the case, our partners at Trade Ideas were the first to inform us of the gains on MYCC. When they did, the CNA Finance team started working to see what was causing the movement. In this particular case, it wasn’t hard to uncover the story. It seems as though the stock is gaining as the result of information about a potential sale.


At the moment, regardless of which social network you use, chances are that you’ll come across the story if you search for ClubCorp Holdings. Essentially, there’s a rumor flying around that the company is working with banks in consideration of selling itself. While I usually advise against jumping at rumors, this one likely has validity to it.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MYCC. In particular, we’re interested in learning if the company has indeed hired banks to help it sell itself. Of course, if this is the case, it could mean that tremendous value will soon be returned to shareholders. We’ll be watching the story closely and bringing it to you as it breaks!

Update: It’s official, my friends. MYCC is indeed looking to sell and is in the early stages of the auction as we speak!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Flickr]

Fiat Chrysler Auto FCAU Stock News

Fiat Chrysler Auto (NYSE: FCAU)

Fiat Chrysler Auto was off to what seemed to be a positive day. When the opening bell rang, the stock was in the green. Unfortunately, that didn’t last long. Shortly after the opening bell, the stock started falling, eventually making it to the red. Then, minutes ago, the stock started to dive further – and in a big way. Below, we’ll talk about what we’re seeing from FCAU, why, and what we’ll be watching for with regard to the stock ahead.





What We’re Seeing From FCAU

As mentioned above Fiat Chrysler Auto looked like it was going to have a strong day during pre-market trading. Unfortunately, when the opening bell rang, things started to change. While the stock started the day off well into the green, it quickly made a run to the red. Then, the stock started to spike downward in a big way as news broke minutes ago. Currently (10:22), FCAU is trading at $10.66 per share after a loss of $0.42 per share (3.79%) thus far today.

Why The Stock Is Falling

As is normally the case, our partners at Trade Ideas were the first to inform us of the drastic fall on FCAU. As soon as they did, the CNA Finance team went to work to see what was causing the movement. In this case, it didn’t take long to dig up the dirt, and unfortunately, it’s not good news for the company.

At the end of the day, it seems as though the losses are being caused by an announcement that was made by the EPA. According to the agency, Fiat Chrysler Auto used software to fool diesel emissions tests. Unfortunately, at the moment, it seems like 100,000 automobiles are included in these claims. Of course, this could prove to be overwhelmingly expensive for the company. As a result, investors are sending the stock downward.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on FCAU. In particular, we’re interested in learning more about the EPA claims and whether or not software was indeed used to fool emissions tests. We’ll be following the story closely and bringing the news to you as it breaks!

Update: FCAU is really on the run now. In just minutes, the stock has fallen to $9.67 per share after a drop of $1.41 per share (12.73%) thus far. Unfortunately, it looks like this thing is going to keep dropping. Put options are incredibly active at the moment.

Update: At 11:04, Fiat Chrysler Auto was halted at $9.29 per share after a loss of $1.80 per share (16.23%) thus far today.

Update: In a statement, Cynthia Giles, Assistant Administrator for EPA’s Office of Enforcement and Compliance Assurance had the following to offer about the issue with FCAU:

“Failing to disclose software that affects emissions in a vehicle’s engine is a serious violation of the law, which can result in harmful pollution in the air we breathe… We continue to investigate the nature and impact of these devices. All automakers must play by the same rules, and we will continue to hold companies accountable that gain an unfair illegal competitive advantage.”

Update: FCAU could face a fine of $37,500 for each vehicle included. Given that 100k vehicles are in the investigation, that’s a whopping $3.75 billion in potential fines!

Update: FCAU opens slightly higher… things still don’t look good!

Update: Fiat Chrysler CEO responds in defense of the company. Says that they will continue selling cars in question as the company has not done anything wrong.

Update: CNBC reporter, Phil LeBeau suggests that the DOJ may be working with the EPA in this case. If so, could criminal charges be the result? We’ll keep you posted!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of Pixabay]

0 3976
Transgenomic Inc TBIO Stock News

Transgenomic Inc (NASDAQ: TBIO)

Transgenomic is off to an incredibly strong start to the trading session today. In pre-market trading, the stock spiked more than 200%. While it has taken a bit of a dive since the opening bell, the stock is still trading on overwhelmingly impressive gains. Below, we’ll talk about what we’re seeing from TBIO, why, and what we’ll be watching for ahead.





What We’re Seeing From TBIO

As mentioned above, Transgenomic is having an overwhelmingly strong day in the market today. In pre-market trading, the stock climbed dramatically on news of a licensing agreement, which we’ll talk about later. When the opening bell rang, the stock was trading up well above 200%. However, since the bell, we’ve seen a bit of a correction. Currently (9:37), TBIO is trading at $0.85 per share after a gain of $0.56 per share (193.64%) thus far today.

Why The Stock Is Gaining

As is almost always the case, our partners at Trade Ideas were the first to inform us of the gains on TBIO. As soon as they did, the CNA Finance team started digging to see exactly what was causing the movement. It didn’t take long to uncover the story in this case. It seems as though the gains are being caused by the fact that the company has announced a licensing agreement.


Early on in the pre-market hours, Transgenomic announced that it had entered into a licensing agreement surrounding the company’s ICE COLD-PCR technology. According to the release, Canadian laboratory services provider, LifeLabs has chosen the company’s technology as its mutation enrichment platform for cancer testing. Of course, this made investors excited and sent the stock upward.

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on TBIO. In particular, we’ll be watching for more licensing agreements to come down the line. After all, this was just one agreement, and we see what it can do to a stock. We’ll keep tabs on the news and be sure to bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required










[Image Courtesy of The Blue Diamond Gallery]

Thought Leader Discussions

Josh Disbrow head shot1 (1)

0 1412
Aytu Bioscience Inc (OTCMKTS: AYTU) Recently, the CNA Finance team had an opportunity to speak with Josh Disbrow, CEO of Aytu Bioscience. Josh Disbrow has...